4-氨基-1-[5-O-[(2R,4S)-2-氧代-4-(4-吡啶基)-1,3,2-二氧磷杂环己烷-2-基]-BETA-D-呋喃阿拉伯糖基]-2(1H)-嘧啶酮 | 685111-92-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 中文名称: 4-氨基-1-[5-O-[(2R,4S)-2-氧代-4-(4-吡啶基)-1,3,2-二氧磷杂环己烷-2-基]-BETA-D-呋喃阿拉伯糖基]-2(1H)-嘧啶酮
• 英文名称: (4S)-5'-O-cis-[4-(pyridin-4yl)-2-oxido-1,3,2-dioxaphosphorinan-2yl]-cytosine-β-D-arabinofuranoside
• 英文别名: 2(1H)-pyrimidinone, 4-amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-arabinofuranosyl]；4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-[[(2R,4S)-2-oxo-4-pyridin-4-yl-1,3,2lambda5-dioxaphosphinan-2-yl]oxymethyl]oxolan-2-yl]pyrimidin-2-one；4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-[[(2R,4S)-2-oxo-4-pyridin-4-yl-1,3,2λ5-dioxaphosphinan-2-yl]oxymethyl]oxolan-2-yl]pyrimidin-2-one
• CAS: 685111-92-6
• 化学式: C₁₇H₂₁N₄O₈P
• 分子量: 440.35
• InChiKey: HOAHIHGOMCBTFW-CCJJFVKCSA-N

物化性质

• 沸点：
  685.3±65.0 °C(Predicted)
• 密度：
  1.80±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  166
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-氨基-1-[5-O-[(2R,4S)-2-氧代-4-(4-吡啶基)-1,3,2-二氧磷杂环己烷-2-基]-BETA-D-呋喃阿拉伯糖基]-2(1H)-嘧啶酮 在 硫酸 作用下， 以 甲醇 为溶剂， 反应 3.25h， 生成 2(1H)-pyrimidinone, 4-amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-arabinofuranosyl]hydrogensulfate salt
  参考文献：
  名称：

  Novel cytarabine monophosphate prodrugs

  摘要：

  式I的化合物，其制备和用途如下所述： 其中： M和V相对于彼此为顺式，MH为紫杉醇； 所述紫杉醇的5′氧原子连接到磷； V为4-吡啶基； 以及其药用可接受的前药和盐。

  公开号：

  US20040092476A1
• 作为产物：
  描述：

  ethyl 3-(L-2-N,N-dimethylamino-3-phenyl-propanoyloxy)-3-(pyridin-4-yl)-propanoate 在 吡啶 、 lithium aluminium tetrahydride 、 叔丁基氯化镁 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 41.0h， 生成 4-氨基-1-[5-O-[(2R,4S)-2-氧代-4-(4-吡啶基)-1,3,2-二氧磷杂环己烷-2-基]-BETA-D-呋喃阿拉伯糖基]-2(1H)-嘧啶酮
  参考文献：
  名称：

  Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-d-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma

  摘要：

  Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. These characteristics lead to poor efficacy, high toxicity, and a drug class associated with an unacceptable therapeutic index. Cyclic 1-aryl-1,3-propanyl phosphate prodrugs selectively release the monophosphate of a nucleoside (NMP) into CYP3A4-expressing cells, such as hepatocytes, while leaving the prodrug intact in plasma and extrahepatic tissues. This prodrug strategy was applied to the monophosphate of the well-known cytotoxic nucleoside cytosine-1-beta-D-arabinofuranoside (cytarabine, araC). Compound 19S (MB07133), in mice, achieves good liver targeting compared to araC, generating > 19-fold higher cytarabine triphosphate (araCTP) levels in the liver than levels of araC in the plasma and > 12-fold higher araCTP levels in the liver than in the bone marrow, representing a > 120-fold and > 28-fold improvement, respectively, over araC administration.

  DOI：

  10.1021/jm0607449

文献信息

• Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
  申请人：Reddy Raja K.

  公开号：US20070021388A1

  公开（公告）日：2007-01-25

  Compounds of Formula I, their preparation and synthetic intermediates, and their use in the synthesis of prodrugs: wherein: V and L are trans relative to one another; V is selected from group consisting of carbocyclic aryl, substituted carbocyclic aryl, heteroaryl, and substituted heteroaryl; and L is a leaving group selected from the group consisting of halogen, alkyl sulfonate, aryloxy optionally substituted with 1-2 substituents, N-containing heteroaryl, and N-hydroxy-nitrogen containing heteroaryl; and salts thereof.

  公式I的化合物，它们的制备和合成中间体，以及它们在前药合成中的应用： 其中：V和L相对于彼此是反式的；V从群组中选择，该群组包括碳环芳基，取代的碳环芳基，杂环芳基和取代的杂环芳基；L是从卤素，烷基磺酸盐，选用1-2个取代基的芳氧基，含氮杂环和含氮氢氧基的杂环中选择的离去基；以及它们的盐。
• NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP1556398B1

  公开（公告）日：2009-09-09
• NUCLEOSIDE PRODRUGS AND USES THEREOF
  申请人：HECKER Scott J.

  公开号：US20120039845A1

  公开（公告）日：2012-02-16

  Compounds having the formula I or II, wherein R 1 , R 2 , B, and V are as defined herein, are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
• US7498320B2
  申请人：——

  公开号：US7498320B2

  公开（公告）日：2009-03-03
• US7553826B2
  申请人：——

  公开号：US7553826B2

  公开（公告）日：2009-06-30